The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

March 30, 2016 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons.

You Might Also Like
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
  • Teva Pharm to Market Medical Cannabis Inhaler in Israel
  • Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors

“They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a telephone interview.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Opioid analgesics are not effective for everyone with chronic pain, carry the risk of addiction, and cause significant mortality and morbidity, Dr. Clauw and his team note in their report, published online on March 19 in the Journal of Pain.

There is some evidence that medical cannabis might be helpful in reducing chronic pain patients’ opioid use, they add, citing a 2014 study that found mortality from opioid overdose fell about 25%, on average, in states that legalized medical cannabis use.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the new study, the researchers surveyed 244 patrons of a medical cannabis dispensary, 185 of whom completed the questionnaire. About two-thirds reported using opioids before starting medical cannabis, while 18% said they continued to use opioids after they began medical cannabis.

On average, patients reported a 64% reduction in their opioid use, and a 45% improvement in their quality of life, after initiating medical cannabis.

The patients also reported a significant drop in the degree to which side effects of medication affected their daily function after starting cannabis, as well as fewer medication side effects.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“They reduced a lot of medications, but the thing that we thought was most impressive both with respect to the magnitude of change and the public health consequences was the fairly dramatic reduction in opioid dose,” Dr. Clauw told Reuters Health.

The study had no external funding. Two coauthors reported disclosures.

Filed Under: Analgesics, Drug Updates Tagged With: Addiction, cannabis, Chronic pain, medical marijuana, Opioids, Pain, Pain Management

You Might Also Like:
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
  • Teva Pharm to Market Medical Cannabis Inhaler in Israel
  • Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors
  • Would Legalizing Medical Marijuana Help Curb the Opioid Epidemic?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)